Outcome of specific COX-2 inhibition in rheumatoid arthritis

Journal of Rheumatology

Volumn 24, Issue SUPPL. 49, 1997, Pages 9-14

  Lipsky, Peter E ^a   Isakson, Peter C ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

Analgesia; Cyclooxygenase; Inflammation; Nonsteroidal antiinflammatory drugs; Prostaglandin; Rheumatoid arthritis

Indexed keywords

CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; INDOMETACIN; MONOCLONAL ANTIBODY; NAPROXEN; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANALGESIA; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EDEMA; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RAT; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RATS; SULFONAMIDES;

EID: 0030787861     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 1971;231:232-5.
2. Smith JH, Willis AL: Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol) 1971;231:235-7.
3. Xie W, Robertson DL, Simmons DL: Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 1992;25:249-65.
4. Fu J-Y, Masferrer JL, Seibert K, Raz A, Needleman P: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
5. Masferrer JL, Sweifel BS, Seibert K, Needleman P: Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375-9.
6. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Natl Acad Sci USA 1991;88:2692-6.
7. O'Banion MK, Sadowski HB, Winn V, Young DA: A serum-and glucocorticoid-regulated 4-calaboose mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991;266:2361-7.
8. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR: TISlO, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;2661:12866-72.
9. Sirois J, Richards JS: Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382-8.
10. Weissmann G: Prostaglandins as modulators rather than mediators of inflammation. J Lipid Med 1993;6:215-86.
11. Weissmann G: Aspirin. Sci Am 1991;1:84-90.
12. Davies P, Bailey PJ, Goldenberg M: The role of arachidonic acid oxygenation products in pain and inflammation. Ann Rev Immunol 1984;2:335-57.
13. Vane JR, Botting RM: Biological properties of cyclooxygenase products. In: Cunningham FM, ed. Handbook of Immunopharmacology. London: Academic Press, 1994:61-97.
14. Mnich SJ, Veenhuizen AW, Monahan JB, et al: Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. J Immunol 1995;155:4437-44.
15. Portanova JP, Zhang Y, Anderson GD, et al: Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996;184:883-91.
16. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA: Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-9.
17. Pairet M, Churchill L, Engelhardt G: Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. In: Bozan N, Botting J, Vane JR, eds. New Targets in Inflammation, Inhibitors of COX-2 or Adhesion Molecules. Dordrecht, Netherlands: Kluwer Academic Publishers, 1996:23-38.
18. Masferrer JL, Zweifel BS, Manning PT, et al: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
19. Seibert K, Zhang Y, Leahy K, et al: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-7.
20. McQueen EG, Facoory B, Faed JM: Non-steroidal antiinflammatory drugs and platelet function. NZ Med J 1986;99:358-60.
21. Cipollone F, Ganci A, Panara MR, et al: Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 1995;58:335-41.